Albumin human
Highest phase reached
Approved
Drug type
Protein
First approval year
1997
- First approval year
- 1997
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Albumin human
- albumin human component of abi 009
- Albumin human component of abi-009
- albuminar 5
- Albuminar-5
- buminate
- Buminate
- plasbumin
- Plasbumin
- abi 009 component albumin human
- ABI-009 COMPONENT ALBUMIN HUMAN
- adebrelimab albumin bound paclitaxel cisplatin
- adebrelimab plus albumin bound paclitaxel carboplatin and recaticimab
- albumin
- Albumin
- ALBUMIN
- Albumin (5% serum-protein solution containing immunoglobulins)
- Albumin (bovine)
- Albumin (human)
- ALBUMIN [VANDF]
- albumin blood
- albumin bound paclitaxel
- Albumin bound paclitaxel
- Albumin Bound Paclitaxel
- albumin bovine
- Albumin bovine
- albumin human
- Albumin human
- Albumin Human
- ALBUMIN HUMAN [II]
- ALBUMIN HUMAN [ORANGE BOOK]
- ALBUMIN HUMAN [USP MONOGRAPH]
- Albumin human [WHO-DD]
- albumin human ii
And 61 more, listed on the interactive page.
- ATC classification codes
- B05AA01
Sources for recorded values
- CAS registry numbers
- 9048-46-8
- ChEMBL ID
- CHEMBL1201451
- FDA ingredient codes (UNII)
- ZIF514RVZR
- 828529
- 1370439
- Applicant
- GE HEALTHCARE
- Approval date
- 31 Dec 1997
- Application number
- NDA020899
- Patents
- 0
- Designations
- 1
- Earliest recorded loss of exclusivity
- 9 May 2028
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- Bilirubin sequestering agent
- Action type
- SEQUESTERING_AGENT
- Target
- Bilirubin
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Subarachnoid Hemorrhage
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000713
- Subject identifier
- D013345
- Condition
- Scleroderma, Systemic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000717
- Subject identifier
- D012595
- Condition
- Liver Cirrhosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001422
- Subject identifier
- D008103
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Kidney Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Pneumonia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Respiratory Distress Syndrome
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003818
- Subject identifier
- D012128
- Condition
- Multiple Sclerosis, Relapsing-Remitting
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003929
- Subject identifier
- D020529
- Condition
- Hypotension, Orthostatic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005252
- Subject identifier
- D007024
- Condition
- Cerebral Hemorrhage
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005669
- Subject identifier
- D002543
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Shock, Septic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006834
- Subject identifier
- D012772
- Condition
- Edema
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009373
- Subject identifier
- D004487
- Condition
- Craniocerebral Trauma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009505
- Subject identifier
- D006259
- Condition
- Burns
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009516
- Subject identifier
- D002056
- Condition
- Macular Degeneration
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009606
- Subject identifier
- D008268
- Condition
- Central Nervous System Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000158
- Subject identifier
- D016543
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000359
- Subject identifier
- D010190
And 23 more, listed on the interactive page.
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000713
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000717
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001422
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003106
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003818
- Condition identifier
- EFO_0004255
- Condition identifier
- EFO_0005252
- Condition identifier
- EFO_0005669
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 2
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007949
- Condition identifier
- EFO_0007949
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009373
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009505
- Condition identifier
- EFO_0009505
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009516
- Condition identifier
- EFO_0009516
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009606
- Highest recorded phase
- 2
- Condition identifier
- EFO_0020910
- Condition identifier
- EFO_0020910
- Highest recorded phase
- 4
And 61 more, listed on the interactive page.
- Event
- acute kidney injury
- Reports
- 54
- Reporting signal score
- 67.7683
- Event
- allergic transfusion reaction
- Reports
- 2
- Reporting signal score
- 9.56061
- Event
- anaphylactic reaction
- Reports
- 36
- Reporting signal score
- 57.9346
- Event
- anaphylactic shock
- Reports
- 15
- Reporting signal score
- 24.3797
- Event
- anaphylactoid reaction
- Reports
- 7
- Reporting signal score
- 16.087
- Event
- arthralgia
- Reports
- 1
- Reporting signal score
- 9.29281
- Event
- atrial septal defect
- Reports
- 7
- Reporting signal score
- 11.9439
- Event
- blood pressure decreased
- Reports
- 20
- Reporting signal score
- 25.6952
- Event
- body temperature increased
- Reports
- 7
- Reporting signal score
- 8.62398
- Event
- brain oedema
- Reports
- 9
- Reporting signal score
- 20.3737
- Event
- bronchopulmonary dysplasia
- Reports
- 5
- Reporting signal score
- 18.4847
- Event
- chills
- Reports
- 32
- Reporting signal score
- 37.3215
- Event
- clostridium test positive
- Reports
- 10
- Reporting signal score
- 38.174
- Event
- diffuse large b-cell lymphoma refractory
- Reports
- 3
- Reporting signal score
- 11.2394
- Event
- drug resistance
- Reports
- 9
- Reporting signal score
- 9.73471
- Event
- dyspnoea
- Reports
- 42
- Reporting signal score
- 9.99732
- Event
- enterococcus test positive
- Reports
- 9
- Reporting signal score
- 42.0537
- Event
- febrile nonhaemolytic transfusion reaction
- Reports
- 2
- Reporting signal score
- 9.15695
- Event
- foetal death
- Reports
- 10
- Reporting signal score
- 29.6122
- Event
- foetal growth restriction
- Reports
- 9
- Reporting signal score
- 20.8708
- Event
- haematochezia
- Reports
- 10
- Reporting signal score
- 8.99429
- Event
- haemodynamic instability
- Reports
- 6
- Reporting signal score
- 12.1533
- Event
- haemorrhage
- Reports
- 15
- Reporting signal score
- 10.6537
- Event
- heart rate increased
- Reports
- 18
- Reporting signal score
- 20.2365
- Event
- hepatitis c antibody positive
- Reports
- 5
- Reporting signal score
- 23.8525
And 35 more, listed on the interactive page.
- NCT00124228
- NCT00428506
- NCT05895136
- NCT00152685
- NCT00220740
- NCT00220779
- NCT00220805
- NCT00235495
- NCT06113848
- NCT06172387
- NCT00263887
- NCT00722475
- NCT00742417
- NCT01524887
- NCT01561053
- NCT00769028
- NCT00773110
- NCT00852800
- NCT00990509
- NCT01420744
- NCT01684462
- NCT01747408
- NCT02055872
- NCT02172937
- NCT02956122
And 47 more, listed on the interactive page.
- Dose
- 25g, 50-75g, 50-100g, 10-50g, 100mL
- Route
- Intravenous
- How often
- As specified per indication (e.g., daily, every 4-12 hours, over 4 hours, every 8 hours, for 3 days)
- Discard unused material
- Do not dilute with sterile water for injection
- Do not start > 4 hours after entry
- Inspect visually before administration
- Warm to room temperature if large volumes
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- 64208-2510
- 64208-2512
Related records
Trials (464)
- "Effect of Albumin Combined With Furosemide in Critically Ill Patients With Fluid Overload: Impact on Urine Output and Renal Function"
- 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid in Cirrhosis With Sepsis Induced Hypotension
- 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
- A Clinical Comparison of Connective Tissue Graft and Alb-PRF for Rebuilding Interdental Papilla
- A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer
- A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
- A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC
- A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).
- A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
- A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
- A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
- A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
- A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.
- A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
- A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
- A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome
Approved for (2)
- Lung disorder
- Nephrosis
In development for (40)
- Adrenoleukodystrophy Phase 2
- Adrenomyeloneuropathy Phase 2
- Alpha 1-antitrypsin deficiency Phase 2
- Alzheimer disease Phase 3
- Amyotrophic lateral sclerosis Phase 2
- Breast cancer Phase 3
- Burn Phase 2
- Central nervous system neoplasm Phase 1
- Cerebral infarction Phase 2
- Chronic inflammatory demyelinating polyradiculoneuropathy Phase 3
- Chronic obstructive pulmonary disease Phase 3
- Cirrhosis of liver Phase 3
- Endometrial cancer Phase 3
- Esophageal squamous cell carcinoma Phase 2
- Exocrine pancreatic carcinoma Phase 3
- Gastric adenocarcinoma Phase 3
- Gastric cancer Phase 3
- Gastroesophageal junction adenocarcinoma Phase 2
- Graft versus host disease Phase 2
- Habitual spontaneous abortion Phase 3
Other linked conditions (2)
- Anemia
- Nephrotic syndrome